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Abstract
Background: Modified Vaccinia Ankara (MVA) is a highly attenuated strain of vaccinia virus (VV)
that has lost approximately 15% of the VV genome, along with the ability to replicate in most
mammalian cells. It has demonstrated impressive safety and immunogenicity profile in both
preclinical and clinical studies, and is being actively explored as a promising vaccine vector for a
number of infectious diseases and malignancies. However, little is known about how MVA interacts
with the host immune system constituents, especially dendritic cells (DCs), to induce strong
immune responses despite its inability to replicate in vivo. Using in vitro and in vivo murine models,
we systematically investigated the susceptibility of murine DCs to MVA infection, and the
immunological consequences of the infection.
Results: Our data demonstrate that MVA preferentially infects professional antigen presenting
cells, especially DCs, among all the subsets of hematolymphoid cells. In contrast to the reported
blockage of DC maturation and function upon VV infection, DCs infected by MVA undergo
phenotypic maturation and produce innate cytokine IFN-α within 18 h of infection. Substantial
apoptosis of MVA-infected DCs occurs after 12 h following infection and the apoptotic DCs are
readily phagocytosed by uninfected DCs. Using MHC class I – deficient mice, we showed that both
direct and cross-presentation of viral Ags are likely to be involved in generating viral-specific CD8+
T cell responses. Finally, DC depletion abrogated the T cell activation in vivo.
Conclusion: We present the first in vivo evidence that among hematolymphoid cells, DCs are the
most susceptible targets for MVA infection, and DC-mediated Ag presentation is required for the
induction of MVA-specific immune responses. These results provide important information
concerning the mechanisms by which strong immune responses are elicited to MVA-encoded
antigens and may inform efforts to further improve the immunogenicity of this already promising
vaccine vector.
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Background
The success of the prototype poxvirus vaccinia virus (VV)
to eradicate naturally occurring smallpox worldwide
stands as one of the most remarkable medical achieve-
ments in human history [1]. This achievement came at a
price, however. Inoculation with live VV can overwhelm
the immune system of immunocompromised individu-
als, causing significant morbidity and mortality [2,3]. As a
result of this realization, toward the end of the smallpox
immunization campaign, a highly attenuated VV strain,
modified vaccinia virus Ankara (MVA), was developed for
use in individuals at high risk of VV-associated adverse
events. MVA has since been safely administrated to over
120,000 individuals in the late stages of the smallpox
eradication effort [4]. MVA lost approximately 15% of the
vaccinia genome in the course of over 500 passages in
chicken embryonic fibroblasts ex vivo, along with the abil-
ity to replicate in most primary mammalian cells [4,5].
Compared to replicating VV, MVA provides similar or
higher levels of endogenous or recombinant gene expres-
sion even in non-permissive cell lines, higher but more
transient Ag expression in vivo, and comparable levels of
immune responses in animal models [6-12]. In light of
this favorable degree of immunogenicity, combined with
its highly attenuated phenotype and associated inherent
safety properties, MVA is being actively explored as a
promising vaccine vector in both preventative and thera-
peutic indications for a number of infectious diseases and
malignancies. In addition, MVA has also been the subject
of renewed interest and clinical evaluation as a safer vac-
cine to prevent smallpox in light of concerns about poten-
tial bioterrorist threats and the increased sensitivity to
vaccine safety considerations especially at a time when far
more individuals with acquired immunodeficiency (by
virtue of either therapeutic immunosuppression or HIV
infection) are present in the population than when the
smallpox eradication campaign was mounted [11,13,14].
Murine models represent an extensively utilized preclini-
cal experimental system for vaccine development. In the
case of MVA, the murine model has been employed, to
date, to study both MVA-induced cellular and humoral
immune responses, as well as the efficacy of protection
following experimental pathogenic VV challenge [15,16].
However, little has been done to understand how this
highly attenuated non-replicating virus activates both
branches of the immune system. Of particular interest,
few systematic studies have been carried out to investigate
the interaction between MVA and murine dendritic cells
(DCs), the most potent APCs to activate naïve CD4 and
CD8 T cells [17]. In contrast, there has been considerable
interest and effort invested in the study of the interaction
of VV and human DCs, and to a somewhat lesser extent,
the interaction between MVA and human DCs [12,18]. VV
has been shown to abortively infect human DCs, block
their maturation, inhibit their phagocytosis and direc-
tional migration, and to induce extensive DCs apoptosis
[19-22]. These observations suggest that targeted infection
of human DCs by VV may be an important viral strategy
to circumvent host immune defenses. All of these studies
employed human monocyte-derived DC (MoDC) cul-
tures. It has not been assessed, in the very tractable murine
model system, how and to what extent specific conse-
quences of poxvirus infection of DC manifested in culture
predict the ability of the host to generate antiviral
immune responses in vivo. Since MVA has lost multiple
host range genes as well as immunomodulatory genes
present in the parental VV genome [5,23], it is conceivable
that the target cell tropism of MVA may differ from that of
VV, and MVA might activate instead of suppress the mat-
uration and function of DC, as suggested for VV.
In the current study, we sought to investigate the follow-
ing questions in murine models: (1) the susceptibility of
DCs to MVA infection; (2) the phenotypic and functional
alteration of DCs upon MVA infection; (3) whether DCs
activate T cells via direct or cross-presentation, and (4)
whether DCs are required for in vivo T cell priming follow-
ing MVA infection. Knowledge gained from these studies
can provide important information concerning the mech-
anisms by which strong immune responses are elicited to
MVA-encoded antigens.
Results
Murine professional APCs are preferentially targeted by 
MVA among hematolymphoid cells, with DCs being the 
most susceptible targets
To study whether murine DCs are susceptible to MVA
infection, naïve BALB/c splenocytes were infected in vitro
with rMVA-GFP at a MOI of 10 for 8 h followed by flow
cytometric detection of EGFP expression in different cell
populations. As shown in Fig. 1A, despite the presumed
broad cellular tropism of VV and related viruses, rMVA-
GFP did not infect all subsets of splenocytes to an equiva-
lent extent, but rather demonstrated a striking preference
for professional APC populations, with CD11c+  DCs
being the most susceptible targets for MVA infection in
the spleen (31.2 ± 2.9% GFP+), followed by CD11b+
CD11c- macrophages (20.1 ± 2.8% GFP+) and CD19+ B
cells (8.5 ± 2.1% GFP+). Very few GFP+ cells were detected
in CD4+ (6.9 ± 1.2%) and CD8+ (3.6 ± 1.5%) T cell popu-
lations. Further phenotypic analysis revealed that over
50% of all GFP+ cells were CD11c+ DCs (data not shown).
Therefore, professional APCs, especially DCs and macro-
phages, seem to be preferentially targeted by MVA among
all the splenocytes subsets in the in vitro infection setting.
This was held true when splenocytes were infected at a
range of MOIs (from 0.3 to 10) (data not shown). At all
the MOIs tested, DCs were by far the most susceptible tar-BMC Immunology 2008, 9:15 http://www.biomedcentral.com/1471-2172/9/15
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gets among all the splenocytes subsets, followed by mac-
rophages and B cells.
To confirm the cellular tropism of MVA infection in vivo,
we infected BALB/c mice intravenously with 3 × 108 PFU
rMVA-GFP. At various time points post infection, spleens
were harvested and MVA infected GFP+ splenocytes were
identified by cell lineage marker staining and flow cytom-
etry. The number of GFP+ cells in spleen peaked at 9 h post
infection and rapidly declined to undetectable level by 24
h post infection (data not shown). At 9 h post infection,
GFP expression was primarily detected in CD11c+ DC
population (12.8 ± 2.1% GFP+), but not any other cell
types including macrophages, as shown in Fig. 1B. This
result suggests that MVA preferentially infects DCs in sec-
ondary lymphoid organ in vivo. Since DCs are vastly out-
numbered by B cells, T cells in spleen, this result, together
with the in vitro infection data (Fig. 1A), establish that
among various subsets of hematolymphoid cells, DCs are
preferentially targeted by MVA in a highly effective man-
ner.
MVA abortively infect murine DCs, with viral life cycle 
arrested before late gene expression
MVA has lost its ability to replicate in most primary mam-
malian cells. The defect in the viral life cycle has been
shown to be the final steps of viral morphogenesis, with
no alteration in early or late virus gene expression [6]. To
determine whether both early and late MVA genes were
expressed from the infected murine DCs, we measured the
expression of GFP (driven by an early promoter) and a
late viral gene A56R from the in vitro MVA-infected
MVA preferentially targeted professional APCs, especially DCs, both in vitro and in vivo Figure 1
MVA preferentially targeted professional APCs, especially DCs, both in vitro and in vivo. (A) Splenocytes from 
naïve BALB/c mice were infected with rMVA-GFP at a MOI of 10 in vitro for 8 h followed by cell surface marker staining and 
flow cytometry analysis. Uninfected splenocytes were used as negative control. (B) BALB/c mice were either uninfected or 
infected with rMVA-GFP at 3 × 108 PFU/mouse by i.v. injection. Spleens were harvested at 9 h post infection and GFP expres-
sion in various subsets of splenocytes was monitored by flow cytometry. DCs: CD11c+; macrophages: CD1b+CD11c-; B cells: 
CD19+; CD8+ T cells: CD8+ CD11c-; CD4+ T cells: CD4+ CD11c-. Numbers shown are the percentages (average ± standard 
deviation (SD)) of GFP+ cells in the corresponding cell subsets. The data are representative of three independent experiments.
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BMDCs as well as purified CD11c+  splenic DCs, as
described in Methods. The permissive chicken embryonic
fibroblasts DF-1 cells were infected in parallel as positive
controls for MVA gene expression. Cells were infected
with rMVA-GFP at a MOI of 10 for 20 h. The cells were
then harvested and subjected to intracellular staining for
anti-A56R mAb, as described in Methods. As shown in Fig.
2, the expression of the early gene GFP was easily detected
in over 60% of cultured BMDCs and 40% of splenic DCs.
However, no A56R (late gene) expression was detected in
either DC preparations (Fig. 2A&B), while almost 100%
DF-1 cells expressed both GFP and A56R. Therefore, the
MVA life cycle is blocked in murine DC at an earlier stage
than the virion assembly defect reported for other non-
permissive mammalian cell lines [6,12]. These data are
consistent with the report that only early but not late MVA
genes are expressed from the infected human DCs [12,24].
Upon MVA infection, BMDC underwent rapid maturation 
and produced significant amount of IFN-α
Targeted infection of MoDC by VV has been suggested as
a viral immune evasion strategy, as DC maturation was
shown to be blocked by VV infection [20,24]. To study
whether MVA infection affects the maturation process of
murine DC, we monitored the expression of maturation
markers by DCs following rMVA-GFP infection. Initially
splenic DCs were used in the experiments. However, these
cells underwent rapid apoptosis within 12 h following in
vitro isolation, even without infection (data not shown).
BMDCs were then used to study the effect of MVA infec-
tion of DC maturation. BMDCs were infected with rMVA-
GFP at a MOI of 10, mock-treated or stimulated with LPS.
Mock-treated BMDCs were used to reflect the spontane-
ous BMDC maturation induced by the "mechanical"
manipulation. LPS treatment was included to induce max-
imal BMDC maturation. At 0, 12 and 18 h following
infection, cells were harvested and stained with mAbs spe-
cific for CD40, CD86, CD80, and MHC class II I-Ad. As
shown in Fig. 3, as early as 12 h post infection there was a
significant upregulation of all the maturation markers on
the majority of infected BMDCs. By 18 h post infection,
the virus-infected DCs further upregulated the maturation
markers. The phenotype of the MVA-infected DCs was
comparable to that of LPS-stimulated DCs at both 12 h
and 18 h post infection. These data suggest that MVA
infection induced rapid BMDC maturation. This is in
direct contrast to the reported blockage of human DC
maturation by VV infection [19,20,24].
Activated DCs secrete an array of cytokines and chemok-
ines that are crucial for amplification of both innate and
adaptive immune responses [17]. To test whether MVA
infection of murine DCs could induce cytokine produc-
tion, we measured the secretion of the pro-inflammatory
cytokine IFN-α from DCs following MVA infection.
BMDCs and splenic CD11c+  DCs were either mock-
treated or infected with rMVA-GFP at a MOI of 10. Super-
natants were harvested at 10 and 24 h post infection, and
Only early but not late MVA genes were expressed from infected DCs Figure 2
Only early but not late MVA genes were expressed from infected DCs. BMDCs (A), splenic CD11c+ DCs (B), and 
DF-1 cells (C) were infected with rMVA-GFP at a MOI of 10. Mock-treated cells were included as negative controls. MVA-
encoded early gene (GFP) and late gene (A56R) expression was monitored 20 h post infection by flow cytometry. The data 
shown are representative of three independent experiments.
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IFN-α levels were measured by ELISA. As shown in Fig. 4,
substantial amount of IFN-α was readily detected from
both BMDC and splenic DCs as early as 10 h after rMVA-
GFP infection. The amount of IFN-α detected in the super-
natant samples was further increased by 24 h post infec-
tion. These results suggest MVA-infected DCs not only
MVA infection induced rapid BMDC maturation Figure 3
MVA infection induced rapid BMDC maturation. Immature BMDCs were mock treated, infected with rMVA-GFP at a 
MOI of 10, or stimulated with 10 μg/ml LPS as described in Methods. At 0, 12 and 18 h post treatment, cells were harvested 
and subjected to cell surface staining for the indicated maturation markers. Samples were analyzed by flow cytometry. Histo-
grams were gated on GFP+ cells. These data are representative of five independent experiments.
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MVA infection induced IFN-αproduction from DCs Figure 4
MVA infection induced IFN-αproduction from DCs. Immature BMDCs (A) or splenic CD11c+ DCs (B) were either 
mock treated or infected with rMVA-GFP at a MOI of 10. Supernatant samples were collected at 10 h and 24 h post infection 
for IFN-α detection by ELISA. These data are representative of three independent experiments.
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undergo rapid phenotypic maturation, but also are capa-
ble of prompting host immune responses via pro-inflam-
matory cytokine production. Noticeably, endogenous
splenic DCs produced significantly higher amount of IFN-
α upon MVA infection compared to BMDCs (5-fold and
3-fold difference at 10 h and 24 h, respectively).
DCs underwent substantial apoptosis following MVA 
infection and were phagocytosed by uninfected DCs
Studies of VV infection of human MoDCs have suggested
that DC undergo substantial apoptosis rapidly following
the infection [12,20]. To study whether this is also true for
MVA infected murine DC, we next assessed the viability of
BMDCs at different time points following MVA infection.
Immature BMDCs were either infected with rMVA-GFP at
a MOI of 10 or mock treated. Cells were harvested at var-
ious time points following the treatment for viability
count. As shown in Fig. 5A, immature BMDCs underwent
substantial apoptosis starting 12 h following MVA infec-
tion, earlier than VV-infected BMDCs which did not
undergo significant apoptosis until 18 h post infection
(unpublished results). By 24 h following infection, only
50% of the MVA-infected cells remained viable, while
90% of mock-treated cells were still alive. Over 70% of the
infected cell had been dead by 42 h following MVA infec-
tion. We further compared the viability of immature and
mature BMDCs following rMVA-GFP infection. BMDCs
were stimulated with LPS for 24 h to reach maturation.
Both immature and mature BMDC were then infected
with rMVA-GFP or mock-treated for 24 h and the cell via-
bility was determined. As shown in Fig. 5B, MVA infection
reduced the viability of both immature and mature BMDC
compared to mock treatment. Interestingly, mature
BMDCs displayed higher viability than immature BMDCs
at this time point. This data suggests that upon matura-
tion, DCs become somewhat more resistant to MVA-
induced cell death. This may be of particular importance
for direct antigen presentation.
The rapid apoptosis of MVA-infected DCs indicates sub-
stantial proportion of infected DCs may not present Ags to
T cells directly, but rather be uptaken by uninfected
bystander DCs for cross-presentation of the viral Ags. We
then investigated whether the MVA- infected DCs under-
going apoptosis could be phagocytosed by uninfected
DCs. Green fluorescence (PKH-67)-labeled BMDCs were
first infected with rMVA for 18 h, then incubated with red
fluorescence (PKH-26)-labeled uninfected BMDCs at 1:1
ratio at either 37°C or 4°C for 4 h. Phagocytosis were
monitored by flow cytometry. Following incubation at
37°C, one third of the uninfected DCs (30.1 ± 5.3%)
became PKH-67+ PKH-26+, while few (2.1 ± 1.9%) unin-
fected DCs picked up PKH-67+ cells at 4°C (Fig. 6). These
data suggest that following MVA infection, the infected
DCs can be engulfed by uninfected DCs efficiently and
rapidly.
MVA-infected DCs can induce viral antigen-specific CTL 
activity in vivo by both direct antigen presentation and 
cross-priming
Having shown that MVA-infected DCs were readily
phagocytosed by uninfected bystander DCs, we then
MVA infection significantly reduced the viability of BMDCs  after 12 h of infection Figure 5
MVA infection significantly reduced the viability of 
BMDCs after 12 h of infection. (A) Kinetic analysis of DC 
viability following MVA infection. Immature BMDCs were 
either mock treated, or infected with rMVA-GFP at a MOI of 
10. At various time points, cells were harvested and viable 
cells were counted with trypan blue exclusion method. 
These data represent the average ± SD viability of 6 repli-
cates from 2 experiments. (B) Immature BMDCs and LPS-
stimulated mature BMDCs were mock treated or infected 
with rMVA-GFP at a MOI of 10. Twenty four hours later, cell 
viability was examined by trypan blue exclusion. These data 
represent the average (± SD) viability of 15 replicates from 5 
experiments. NS: statistically non-significant; *: P < 0.05; **: P 
< 0.01.
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hypothesized that MVA Ags can be presented to T cells
through cross-presentation. To test this hypothesis, rMVA
expressing LCMV NP Ag (rMVA-NP) or rMVA-GFP was
used to infect BMDCs from either WT C57BL/6 mice or
MHC class I deficient β2m-/- mice. DCs were infected at a
MOI of 10 for 6 h before intravenously injected into
LCMV immune mice. To prevent direct infection of host
APCs by the infectious viruses co-injected with BMDCs,
DCs were extensively washed and irradiated prior to the
injection. Five days following DC injection, spleens were
harvested and single cell suspensions were prepared and
CTL activity specific to the dominant LCMV epitope
NP396–404 was determined by fluorescent cellular cytotox-
icity assay, as described in Methods. Strong NP396–404 –
specific CTL activity was detected in mice immunized by
rMVA-NP-infected WT DCs, but not in mice immunized
with rMVA-GFP-infected BMDCs (Fig. 7). Interestingly,
NP396–404-specific CTL activity was also detectable,
although to a lesser degree, in mice immunized with
rMVA-NP-infectedβ2m-/- DCs. Since β2m-/- DCs cannot
directly present MHC class I-restricted Ags to T cells, these
data suggest that the detected CTL activity is due to cross-
presentation of NP Ags by the endogenous APCs that have
phagocytosed the injected β2m-/- DCs.
In vivo DC depletion abrogated the production of effector 
cytokine IFN-γ by T cells following MVA infection
To definitively answer the question whether DCs are
responsible and required for the in vivo T cell activation
following MVA infection, we took advantage of the
CD11c-DTR mice that express human DT receptor under
the control of the CD11c [25]. DT injection has been
shown to effectively deplete CD11c+ DCs within 24 h. We
depleted DCs from CD11c-DTR mice by i.p. injection of
DT (12 ng/g body weight) [25,26] and infected the mice
with 5 × 106 PFU MVA intraperitoneally 18 h later. DT
injection was repeated on day 2 after infection to ensure
continuous absence of DC. On day 6 after MVA infection,
spleens were harvested and the efficiency of DC depletion
was determined by flow cytometry. Over 95% of CD11c+
DCs were depleted and the residual DCs had CD11clow
B220+ phenotype, similar to that of plasmacytoid DCs
(Fig. 8A). Single cell suspensions prepared from the
spleens were re-stimulated with C57BL/6 splenocytes
infected with MVA for 6 h in the presence of Brefeldin A.
Following the re-stimulation, the frequencies of IFN-γ-
producing effector CD3+ T cells specific for MVA antigens
were determined by intracellular IFN-γ-staining, as
described in Methods. As shown in Fig. 8B, MVA-specific
effector T cells producing IFN-γ were detected in the
spleens of WT littermates on day 6 after MVA infection.
These cells accounted for 1.75 ± 0.05% of total CD3+ T
cells (Fig. 8C). However, in DC-depleted CD11c-DTR
mice, we failed to detect any IFN-γ-production from CD3+
T cells (Fig. 8B and 8C). These data suggest that DC-medi-
ated Ag presentation is required for the generation of IFN-
MVA-infected DCs induced Ag-specific CTL in vivo via both  direct Ag presentation and cross-priming Figure 7
MVA-infected DCs induced Ag-specific CTL in vivo 
via both direct Ag presentation and cross-priming. 
BMDCs derived from either WT C57BL/6 (WT DCs) or 
MHC class I-deficient β2m-/- mice (β2m-/- DCs) were infected 
with rMVA-NP or control rMVA-GFP at a MOI of 10 for 6 h. 
The cells were washed and UV-irradiated to remove and 
inactivate any residual viruses. DCs were then intravenously 
injected into LCMV immune C57BL/6 mice 1 × (106). Five 
days later, NP396–404-specific CTL activity in spleens was 
assessed by fluorescent cellular cytotoxicity assay, as 
described in Methods. *: P < 0.05.
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MVA-infected DCs were phagocytosed by uninfected DCs Figure 6
MVA-infected DCs were phagocytosed by uninfected 
DCs. Immature BMDCs were labeled with PKH-67 and 
infected with MVA at a MOI of 10 for 18 h. They were then 
extensively washed and mixed with PKH-26-labeled unin-
fected immature BMDCs for 4 h at either 37 C° or 4 C°. 
Phagocytosis of MVA-infected DCs by uninfected DCs were 
detected by flow cytometry. This data is representative of 
two independent experiments.
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γ producing effector T cells in vivo following MVA infec-
tion.
Discussion
rVVs are established tools for the development of vaccines
against a wide range of infectious and malignant diseases
[15,16]. Concerns about the safety of VV have led to the
use of replication-defective viral vector systems, of which
MVA is considered one of the safest and most promising
candidates. Currently, at least three types of approaches
have been used in MVA-based vaccine development [11]:
(1) administration of MVA as primary vaccine or as a
priming vector in the case of rMVAs expressing heterolo-
gous antigens; (2) administration of rMVA as booster vac-
cine following a primary immunization with an
alternative vector encoding the same antigen of interest,
such as delivered via DNA vaccination; and (3) immuni-
zation with DCs infected ex vivo with rMVA. Immuno-
genicity studies have shown that, compared to the
replicating conventional VV vaccines, MVA vaccines can
achieve similar or even higher levels of cellular and
humoral responses and protect animals from lethal poxvi-
rus challenge [6-12,27]. Although the mechanisms by
which this highly attenuated non-replicating virus
induces strong immune responses is not well-understood,
it is conceivable that all these approaches ultimately
depend on the capacity of DCs to induce Ag-specific T cell
responses – given the central role of DCs in generating
innate and adaptive immune responses. This is supported
by the recent report that CD11c+  DCs isolated from
Peyer's Patches and spleens of both MVA and VV-immu-
nized mice induced substantial IFN-γ production from an
antigen-specific CTL line [27], although whether cell sub-
sets other than DCs from the same lymphoid tissues could
also be loaded with Ags and activate T cells was not tested
in the study.
Current knowledge of the interaction of poxviruses with
DCs is mostly derived from the studies of VV infection of
human DC cultures. These studies have shown that VV
abortively infects human MoDCs, inhibits their matura-
tion, phagocytosis, and migration, and reduces the ability
to stimulate allogeneic or autologous T cells in vitro [19-
22,24,28]. The suggestion that the perturbation of DC
physiology observed in tissue culture infections of human
DCs reflect a fundamental strategy of viral immune eva-
sion is difficult to reconcile with the substantial humoral
and cellular immune responses generated in VV-vacci-
nated individuals [29-31]. Whether the results from the in
vitro studies accurately depict the in vivo VV-DC interac-
tion is still an open question. Conflicting data have
recently been reported regarding MVA infection of DCs. In
one study, MVA was shown to induce immature human
MoDC activation, based on the upregulation of co-stimu-
latory molecules and the secretion of pro-inflammatory
DCs were required for the generation of IFN-γ-producing  effector T cells following MVA infection Figure 8
DCs were required for the generation of IFN-γ-pro-
ducing effector T cells following MVA infection. 
CD11c-DTR mice were depleted of DC by i.p. injection of 
DT (12ng/g body weight). Six hours after DT treatment, mice 
were i.p. infected with 5 × 106 PFU MVA. DT treatment was 
repeated on day 2 post infection. WT littermates were 
included as controls. At day 6 following the infection, spleens 
were harvested to prepare single cell suspension. (A) The 
efficiency of DC depletion was determined by surface cell lin-
eage marker staining and flow cytometry. Numbers were the 
percentages of the gated population in total viable spleno-
cytes. (B, C) Spleen single cell suspension (effector) was re-
stimulated with MVA-infected C57BL/6 splenocytes (target) 
for 12 h in the presence of Brefeldin A. Following incubation, 
the frequencies of IFN-γ-producing T cells in the effector 
splenocytes were determined by intracellular cytokine stain-
ing, as described in Methods. Numbers were the percentages 
of IFN-γ+ cells in CD3+ T cell population. (C) The average ± 
SD percentages of IFN-γ+ cells for each group (n = 4). Data 
are representative of two independent experiments. **: P < 
0.01.
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cytokines [18]. Another study showed that MVA-infected
immature human MoDCs failed to undergo maturation,
but nevertheless were able to present viral Ags to the Ag-
specific human CTL line [12]. Using a murine model,
Belyakov et al showed that endogenous DCs isolated from
MVA immunized mice stimulated murine CTL lines in
vitro [27]. However, the CTL lines used in these studies
may have less stringent requirement than primary naïve T
cells for co-stimulatory signals provided by APCs. Priming
of naïve CD8+ T cells in mice immunized with MVA-
infected immature BMDCs was demonstrated by Beh-
boudi et al, even though the infected BMDCs downregu-
lated MHC class I molecules and underwent apoptosis
[32,33]. It was unclear in these studies whether MVA Ags
were presented directly by MVA- infected DCs or indi-
rectly via cross-presentation in these studies.
In the current report, we systematically characterized the
interaction of MVA and host DCs using both in vitro and
in vivo murine models to understand the role of DCs in
MVA-induced immunogenicity. Using two different
approaches, in vitro infection of splenocytes and in vivo
infection of experimental mice, we first demonstrated that
DCs are preferentially infected by MVA among various cel-
lular components of the adaptive immune system (Fig. 1).
This is consistent with our recent report of a similar DC
tropism for VV infection in human PBMC [28]. Thus,
despite the extensive loss of parental vaccinia host range
genes from the MVA genome, the unique DC tropism of
VV is well-conserved in MVA and thus may be of great bio-
logical importance for the interactions between poxvi-
ruses and the host immune system. The search for the
cellular receptor(s) required for poxvirus binding and
entry has continued for decades with little success. Our
data suggest that the identification of poxvirus receptor(s)
on DCs may greatly facilitate the design of DC-targeting
Ag delivery system to further improve vaccine immuno-
genicity.
Infection of DCs by viruses could be either beneficial or
harmful for the host immune system, depending on the
subsequent phenotypic and functional changes of the
infected DCs. For example, influenza virus and dengue
virus infections lead to DC maturation and efficient T cell
activation [34,35]. Consequently, the viruses are quickly
cleared with resolution of the acute infection period. On
the other hand, three viruses known to induce immuno-
suppression in humans, CMV, measles, and HIV, have all
been documented to infect DCs directly and induce
adverse functional alterations [36-39]. Our data support
the contention that MVA infection efficiently induces
murine DC maturation, manifested by the up-regulation
of DC maturation markers (Fig. 3). We also demonstrated
that following MVA infection, both BMDCs and splenic
DCs secreted substantial amount of pro-inflammatory
cytokine IFN-α (Fig. 4). These observations provide a
rational explanation of MVA-induced immunogenicity,
but are in direct contrast with the reported impairment of
human DC maturation and function following VV infec-
tion [19-22,24,28]. The discrepancy could be attributed to
or explained by a number of possibilities. First, it has been
shown that, when viral gene expression was prevented by
UV light or heat treatment, VV induced rapid human DC
activation [18]. This suggests that the de novo synthesis of
VV-encoded gene products interferes with DC maturation
induced by viral binding or internalization per se. It is
therefore possible that MVA infection of DCs may lead to
distinct immunological consequences due to the deletion
of the inhibitory genes from MVA genome. Second, MVA
but not VV infection was shown to activate NF-κB in
human embryonic kidney cells [40,41]. Since NF-κB acti-
vation is essential for DC activation and Ag presentation
[40,41], it is possible that MVA but not VV infection acti-
vates NF-κB-dependent pathways in DCs leading to their
maturation. Third, in a concurrent study, we observed
rapid maturation of murine BMDCs upon VV infection
(unpublished data), suggesting possible species-specific
and/or DC subtype-specific differences in the conse-
quences of poxvirus infection on DCs.
Comparative studies of the MVA and VV genomes have
revealed that many VV immune evasion genes that target
host cytokine and chemokine functions have been lost
from the MVA genome [5,42]. This has been proposed to
at least partially compensate for the inability of MVA to
replicate and sustain Ag production within hosts. Here,
we show that a substantial amount of IFN-α was detected
in the supernatant of MVA- infected DCs (both BMDCs
and splenic DCs). Interestingly, when VV was used to
infect BMDCs and splenic DCs, we failed to detect any
IFN-α in the supernatant [see Additional figure 1A]. Fur-
thermore, when known amount of recombinant IFN-α
was added into the supernatant samples prior to ELISA,
the recombinant IFN-α was no longer detected when
added into VV-infected, but not MVA-infected, DC super-
natant [see Additional figure 1B]. These data are consist-
ent with the facts that vaccinia B18R gene encodes soluble
high-affinity IFN-α/β receptors and the B18R gene has
been deleted from the MVA genome [43-45]. The impor-
tance of type I IFNs in the protective immunity against
poxvirus infection is manifested by the attenuated viru-
lence of B18R-knockout VV in both intranasally and
intracranially infected mice [43,44]. Since type I IFN pro-
mote DC maturation and support CD8+ T cell and Th1
responses [46,47], IFN-α released from MVA-infected cells
may contribute to the maturation of DCs following MVA
infection and the subsequent induction of innate as well
as cellular immune responses.BMC Immunology 2008, 9:15 http://www.biomedcentral.com/1471-2172/9/15
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We observed substantially reduced DC viability following
MVA infection (Fig 5A). By 24 h after the infection, over
50% of DCs died. Similar to VV-induced cytopathy of
human MoDC [20], we found that mature murine DCs
are more resistant than immature murine DCs to MVA-
induced death (Fig. 5B), and that MVA infection induced
more DC apoptosis than VV infection (data not shown).
The relatively higher susceptibility of DCs for MVA-
induced cell death is consistent with our recent report
that, compared with VV, MVA infection of human MoDCs
leads to accelerated decline of intracellular anti-apoptosis
genes Bcl-2 and Bcl-L [24]. Deletion of the anti-apoptosis
gene SPI-2 from the MVA genome may also contribute to
decreased DC viability following infection [24,48]. Our in
vivo experiments provide further evidence for rapid DC
apoptosis upon rMVA infection. Following intravenous
infection of mice with rMVA-GFP, the number of GFP+
cells in the spleen peaked at 9 h post infection and
dropped sharply to background levels by 24 h post infec-
tion (data not shown). This result is in agreement with a
report by Norbury et al which showed that the numbers of
VV-infected cells in the draining lymph nodes following
footpad injection decreased by 80% between 6 and 24 h
post infection [49]. Although it is possible that the
infected DCs were killed by a virus-specific immune
response, as hypothesized by the authors, we think it is
unlikely that naïve T cells could be called into action to
kill in such a short period of time. Thus the disappearance
of infected cells is more likely due to the direct cytopathic
effect of the virus infection, as seen in our in vitro experi-
ments.
It has been controversial whether T cell activation follow-
ing poxvirus immunization is mainly due to direct Ag
presentation by virus-infected DCs, rather than cross-pres-
entation of viral Ags by uninfected DCs that have picked
up the infected apoptotic cells [49]. Rapid maturation of
MVA-infected DCs suggests that these DCs can directly
activate T cells before they undergo apoptosis. On the
other hand, substantial DC apoptosis in vitro and in vivo
following MVA infection indicates that direct Ag presenta-
tion by the infected DCs is likely to diminish quickly and
that cross-presentation of viral Ag by uninfected bystander
DCs might be involved after the majority of the infected
DCs have undergone apoptosis. In support of this hypoth-
esis, we observed efficient phagocytosis of MVA-infected
DCs by uninfected DCs (Fig. 6). Furthermore, when MVA-
infected β2m-/- DCs were injected into mice, Ag-specific
CTL activity was detected in the spleens, although at a
lower level than in mice that received MVA-infected WT
DCs. Similarly, Norbury et al. has shown that β2m-/- kid-
ney cells infected with VV induced CD69 upregulation of
Ag-specific CD8+ T cells in vivo [50]. These results strongly
suggest that both direct and cross-priming of CD8 T cells
occur following poxvirus infection. CD8+ T cell cross-
priming is further supported by the identification of late
poxvirus gene-derived CTL epitopes in both human and
mice [51], since the inability of DCs infected by either VV
or MVA to express late viral genes prevents the direct pres-
entation of late viral Ags.
We also observed MVA infection of macrophages and B
cells, although to a lesser degree comparing to DCs. It
remains unclear whether these cells can also present viral
Ags and activate T cells in vivo following MVA infection.
Using the CD11c-DTR mouse model that allows the con-
ditional ablation of DCs in vivo, we unambiguously dem-
onstrated that DC depletion abrogated the generation of
Ag-specific effector T cells (IFN-γ-producing). Therefore,
DCs (but not other APCs) play an essential role in the gen-
eration of MVA-specific T cells in vivo. The preferential
infection of DCs by poxviruses could serve as an efficient
Ag delivery system to the most crucial APCs for the induc-
tion of strong immune responses.
Conclusion
In summary, we present here the first systematic study of
the interaction of MVA and murine DCs, using both in
vitro and in vivo model systems. We demonstrate that pro-
fessional APC, especially DCs, are preferentially targeted
by MVA in secondary lymphoid tissues. The infected DCs
express high levels of viral early Ags, undergo rapid matu-
ration during the first 12 h post infection, produce sub-
stantial amount of IFN-α, then become apoptotic in the
next 24 h. The infected DCs are readily taken up by unin-
fected bystander DCs, with their protein constituents then
made available via cross-presentation mechanisms of
antigen presentation to elicit virus-specific adaptive
immune responses. DCs are required for the in vivo T cell
activation, most likely via both direct- and cross-presenta-
tion of viral Ags. These results contribute to our under-
standing of the strong immunogenicity associated with
the highly attenuated MVA and may be of great value for
the design of safer and more effective vaccine vectors.
Methods
Mice
All animal work has been reviewed and approved by the
Center for Animal Resources and Comparative Medicine
at Emory University and Harvard Medical School. 6- to 8-
week-old female BALB/c mice and C57BL/6 mice were
purchased from the Jackson Laboratories (Bar Harbor,
ME). MHC class I-deficient B6.129P2-B2mtm1Unc (β2m-/
-) mice and CD11c-DTR-EGFP (CD11c-DTR) breeders
[25] were purchased from the Jackson Laboratories and
bred in a biosafety level-1 facility at Harvard Medical
School. Virus-infected mice were housed in a biosafety
level -2 facility.BMC Immunology 2008, 9:15 http://www.biomedcentral.com/1471-2172/9/15
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Virus stocks
rMVA strains were constructed to express GFP-ZEOCIN
(rMVA-GFP) or lymphocytic choriomeningitis virus
(LCMV) nuclear protein (NP) -ZEOCIN (rMVA-NP)
[28,52] under the control of the early H5 promoter and
were plaque-purified at least 5 times as previously
described using standard protocol [53]. Non-recom-
binant MVA stock used for the construction of rMVA was
kindly provided by Dr. Bernard Moss (National Institutes
of Health, Bethesda, MD). MVA for the phagocytosis
experiment and for the infection of CD11c-DTR mice
were kindly provided by Dr. Michael S. Seaman (Beth
Israel Deaconess Medical Center, Boston, MA). rMVA-GFP
and rMVA-NP stocks were prepared in and titered on the
chicken embryo fibroblast cell line DF-1 (gift of Dr.
Harold Varmus, National Institutes of Health, Bethesda,
MD). Viruses were concentrated by ultracentrifugation
over 36% (weight/volume) sucrose, and titers were deter-
mined using standard plaque assays. LCMV stocks (Arm-
strong strain) were kindly provided by Dr. Rafi Ahmed
(Emory Vaccine Research Center, Atlanta, GA).
Cells
DF-1 and HeLa cells are described above. These cell lines
were maintained in complete DMEM supplemented with
10% FBS, 2 mM L-glutamine and antibiotics. EL4 cells (H-
2b) (ATCC) were maintained in RPMI supplemented with
10% FBS, 2 mM L-glutamine and antibiotics. Splenic DCs
were isolated from the spleens of BALB/c mice that
received daily injections of 20 μg of recombinant flt3L-
IgG2 for 9 days [54,55]. Briefly, spleen fragments were
digested with 1 μg/ml collagenase (Worthington, Lake-
wood, NJ) for 30 min, followed by erythrocyte depletion
with RBC lysing buffer (Sigma-Aldrich Co., St. Louis,
MO). DCs were then isolated from this single cell suspen-
sion using CD11c magnetic beads (Miltenyi Biotec,
Auburn, CA) according to the manufacturer's instructions,
and the purity of DCs was greater than 90% as evaluated
by flow cytometry (data not shown).
Bone marrow-derived DCs (BMDCs) were generated from
mouse bone marrow cultures as described previously with
minor modifications [56]. Briefly, bone marrow was
flushed from femurs and tibias and depleted of erythro-
cytes with RBC lysing buffer. Cells were subsequently
plated on 6-well tissue culture plates at 4 × 106/well in 3
ml complete RPMI 1640 medium (CM, contains 10%
FBS, 2 mM L-glutamine, and 10 μg/ml gentamicin sul-
fate), incubated at 37°C for 3 h, and then the non-adher-
ent cells were removed. CM containing 10 ng/ml rmGM-
CSF and 3 ng/ml rmIL-4 (both from R&D Systems, Min-
neapolis, MN) was added at 3 ml per well and the plates
were incubated at 37°C for 1 week. Cultures were fed by
gently aspirating 2 ml/well of medium and adding back
fresh CM containing cytokines on days 2, 4 and 6 of the
culture. When mature DCs were required, 10 μg/ml LPS
(Sigma-Aldrich Co.) was added to the culture on day 6 for
24 h. On day 7, non-adherent cells were harvested, and
the purity of the DCs culture was evaluated by cell surface
staining with fluorescence-conjugated mAbs to CD11b
(M1/70), CD11c (HL3), CD3 (145-2C11), and CD45R/
B220 (RA3-6B2) (BD Biosciences Pharmingen, San Diego,
CA). Approximally 70–90% of the cells were CD11c+, as
determined by flow cytometry (data not shown).
Viral infection
For in vitro infections, cells were resuspended at 1 × 107/
ml CM in 15 ml polypropylene tubes (Becton Dickinson
Labware). An appropriate volume of the indicated virus
stock was added to reach the multiplicity of infection
(MOI) required for each experiment. Following 1 h-incu-
bation at 37°C, cells were washed three times with
medium, resuspended at 1 × 106/ml in CM on 24-well
plates and cultured at 37°C until harvesting. Mock-treated
cells were manipulated in the same way except that no
virus was added. For in vivo i.v. infection, BALB/c mice
were i.v. injected with 15 μg DNA plasmid pNGVL3-hFLex
[57] (obtained from National Gene Vector Laboratory,
University of Michigan, and provided by Dr. Abdul M.
Jabbar, Emory Vaccine Center) in 1.6 ml PBS to expand
DC population in vivo. Five days later, mice were infected
i.v. with 3 × 108 plaque forming units (PFU) of rMVA-GFP
in 0.5 ml PBS. Uninfected mice were injected with 0.5 ml
PBS as controls. For intraperitoneal (i.p.) infection,
CD11c-DTR mice and wild type (WT) littermates were
infected with 2 × 106 PFU MVA.
Cell surface staining and flow cytometry
At the indicated time points post viral infection, spleno-
cytes were stained with mAbs against CD3, B220, CD11b,
CD11c, CD8a (Ly-2) (53-6.7), and CD4 (L3T4) (RM4-5)
(BD Biosciences Pharmingen). At the indicated time
points following in vitro infection, DF-1 cells, BMDCs, and
splenic DCs were stained with purified anti-vaccinia late
surface protein A56R using mAb VV1-4G9 (kindly pro-
vided by Dr. Alan Schmaljohn, USAMRIID, Frederick,
MD) and secondary PE-conjugated goat anti-mouse IgG
(Biosource International, Camarillo, CA). BMDCs and
splenic DCs were also stained with mAbs against DC mat-
uration markers CD80 (16-10A1), CD86 (GL1), CD40
(5C3), and I-Ad (AMS-32.1) (BD Biosciences Pharmin-
gen). All staining steps were performed by incubating cells
and Abs at 4°C for 20 min followed by three washes with
staining buffer. Samples were then processed using a FAC-
SCalibur flow cytometer (Becton Dickinson Labware) and
the data were analyzed using Flowjo software (Tree Star,
Inc., Ashland, OR).BMC Immunology 2008, 9:15 http://www.biomedcentral.com/1471-2172/9/15
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Quantitation of IFN-α production by ELISA
BMDCs or splenic DCs were mock- treated or infected
with rMVA-GFP. Supernatant samples were harvested at
10 or 24 h following the treatment and stored at -80°C if
not used immediately. IFN-α in the supernatant was
detected using a commercial colorimetric sandwich ELISA
kit (R&D Systems) according to manufacturer's instruc-
tions.
Viability study
Viability of BMDCs was determined by trypan blue exclu-
sion at various time points following infection.
Phagocytosis assay
BMDCs were labeled with the green fluorescent dye PKH-
67 (Sigma-Aldrich Co.) according to the manufacturer's
instructions and infected with MVA at a MOI of 10 for 18
h. They were then mixed with uninfected immature
BMDCs labeled with the red fluorescent dye PKH-26
(Sigma-Aldrich Co.) for 4 h at either 37°C or 4°C. Phago-
cytosis of infected DCs by uninfected DCs (PKH-67+ PKH-
26+ population) was visualized by flow cytometry.
BMDC immunization and detection of cytotoxic T 
lymphocyte (CTL) activity
BMDCs derived from either WT C57BL/6 mice (B6.DCs)
or β2m-/-mice (β2m-/-DCs) were infected with rMVA-NP
or control rMVA-GFP at a MOI of 10 for 6 h. The cells were
then extensively washed with PBS and UV-irradiated to
inactivate any residual viruses and prevent co-injection of
infectious MVA. They were then injected (1 × 106) into B6
mice that had been i.p.-infected with 2 × 105 PFU LCMV
30 days earlier. Five days after the DC injection, spleens
were harvested and NP396–404-specific CTL activity was
assessed by fluorescent cellular cytotoxicity assay as previ-
ously described [58]. Briefly, target EL4 cells were incu-
bated at 37°C 5% CO2 for 1 h in the presence of 1 μM
NP396–404 peptide and 3 μM cell tracker orange (CTO, Inv-
itrogen, Carlsbad, California). Cells were washed once
with PBS and resuspended in CM at 1 × 106/ml. Target
cells and effector splenocytes from BMDC-immunized
mice (100 μl) were co-cultured on 96-well U-bottom
plates for 4 h at 37°C 5% CO2. The cells were then pel-
leted and incubated in 75 μl/well fluorogenic caspase 3
substrate R2D2 (10 μM, kindly provided by Dr. Beverly
Packard, OncoImmunin Inc., Gaithersburg, MD) for 30
min followed by two washes with cold PBS. Sample acqui-
sition and analysis are as described above. The cleaved
caspase substrate has the following fluorescence peak
characteristics: λex = 505 nm and λem = 530 nm, and can
be detected in the FL1 channel. CTO can be detected in the
FL2 channel. The percentage of specific killing = [% cas-
pase+  CTO+  cells/(% caspase+  CTO+  cells + % caspase-
CTO+ cells)] × 100%.
In vivo DC depletion and intracellular IFN-γ staining
Age and gender-matched CD11c-DTR mice and WT litter-
mates were injected i.p. with 12 ng/g body weight of diph-
theria toxin (DT) (List Biological Laboratories, Campbell,
CA) on day 0 and day 2 [25,26]. Six hours after the first
DT injection, mice were infected i.p. with MVA at 5 × 106
PFU. Spleens were harvested on day 6 following the infec-
tion. Efficiency of DC depletion was determined by flow
cytometry. Single cell suspensions (effector cells) were
incubated with MVA-infected naïve splenocytes (target
cells) in 96-well U-bottom plate (106/well effector and
target cells each) in the presence of GolgiStop (BD Bio-
science) for 12 h. Cells were then blocked with anti-
CD16/CD32 FcγR III/II (2.4G2) and subjected to surface
staining with anti-CD3 and CD8, as described above. Sub-
sequent intracellular staining was performed using anti-
mouse IFN-γ (XMG1.2), rat-IgG1 isotype control (R3-34),
and CytoFix/CytoPerm kit (BD Biosciences) according to
manufacturer's instructions.
Statistical analysis
All statistical analyses were made with Microsoft Excel
software (Microsoft). Statistical comparisons between
data sets were made with a two-tailed homoscedastic Stu-
dent's t-test.
List of abbreviations
VV: vaccinia virus; MVA: Modified vaccinia Ankara; DC:
dendritic cell; MoDC: monocyte-derived DC; DTR: diph-
theria toxin receptor; LCMV: lymphocytic choriomeningi-
tis virus; NP: nuclear protein; BMDC: bone marrow
derived DC; CM: complete medium; MOI: multiplicity of
infection; PFU: plaque forming unit; i.p., intraperitoneal;
WT: wild type; CTL: cytotoxic T lymphocyte; CTO: cell
tracker orange; DT: diphtheria toxin.
Authors' contributions
LL designed, performed and analyzed all the experiments,
wrote the manuscript. RC created the rMVA-GFP and
rMVA-NP, and generated data in Fig. 2B. MBF participated
in the design of the experiment and interpretation of data,
revised the manuscript critically for important intellectual
content. All authors read and approved the final manu-
script.BMC Immunology 2008, 9:15 http://www.biomedcentral.com/1471-2172/9/15
Page 13 of 14
(page number not for citation purposes)
Additional material
Acknowledgements
We thank Dr. Thomas S. Kupper, Chair of Dermatology Department at 
Brigham and Women's Hosptial, for reviewing the manuscript and provid-
ing general support; Dr. Qiong Zhong for the assistance in CD11c-DTR 
mice genotyping, Jay Omobono for help in formatting the illustrations. This 
study was supported by Dermatology Foundation Research Career Devel-
opment Award, New England Research Center of Excellence/Biodefense 
and Emerging Infectious Diseases Career Development Fellowship to LL, 
NIH grant P01A146007-05 to MBF, and NIH/NIAID grant U19 AI057330-
03 to TSK.
References
1. Willis NJ: Edward Jenner and the eradication of smallpox.
Scott Med J 1997, 42(4):118-121.
2. Neff JM, Levine RH, Lane JM, Ager EA, Moore H, Rosenstein BJ, Millar
JD, Henderson DA: Complications of smallpox vaccination
United States 1963. II. Results obtained by four statewide
surveys.  Pediatrics 1967, 39(6):916-923.
3. Neff JM, Lane JM, Pert JH, Moore R, Millar JD, Henderson DA: Com-
plications of smallpox vaccination. I. National survey in the
United States, 1963.  New England Journal of Medicine 1967,
276(3):125-132.
4. Mayr A, Stickl H, Muller HK, Danner K, Singer H: [The smallpox
vaccination strain MVA: marker, genetic structure, experi-
ence gained with the parenteral vaccination and behavior in
organisms with a debilitated defence mechanism (author's
transl)].  Zentralbl Bakteriol [B] 1978, 167(5-6):375-390.
5. Meyer H, Sutter G, Mayr A: Mapping of deletions in the genome
of the highly attenuated vaccinia virus MVA and their influ-
ence on virulence.  J Gen Virol 1991, 72(Pt 5):1031-1038.
6. Sutter G, Moss B: Nonreplicating vaccinia vector efficiently
expresses recombinant genes.  Proceedings of the National Acad-
emy of Sciences of the United States of America 1992,
89(22):10847-10851.
7. Ramirez JC, Gherardi MM, Esteban M: Biology of attenuated
modified vaccinia virus Ankara recombinant vector in mice:
virus fate and activation of B- and T-cell immune responses
in comparison with the Western Reserve strain and advan-
tages as a vaccine.  Journal of virology 2000, 74(2):923-933.
8. Wyatt LS, Earl PL, Eller LA, Moss B: Highly attenuated smallpox
vaccine protects mice with and without immune deficiencies
against pathogenic vaccinia virus challenge.  Proceedings of the
National Academy of Sciences of the United States of America 2004,
101(13):4590-4595.
9. Earl PL, Americo JL, Wyatt LS, Eller LA, Whitbeck JC, Cohen GH,
Eisenberg RJ, Hartmann CJ, Jackson DL, Kulesh DA, Martinez MJ,
Miller DM, Mucker EM, Shamblin JD, Zwiers SH, Huggins JW, Jahrling
PB, Moss B: Immunogenicity of a highly attenuated MVA
smallpox vaccine and protection against monkeypox.  Nature
2004, 428(6979):182-185.
10. Belyakov IM, Earl P, Dzutsev A, Kuznetsov VA, Lemon M, Wyatt LS,
Snyder JT, Ahlers JD, Franchini G, Moss B, Berzofsky JA: Shared
modes of protection against poxvirus infection by attenu-
ated and conventional smallpox vaccine viruses.  Proceedings of
the National Academy of Sciences of the United States of America 2003,
100(16):9458-9463.
11. Drexler I, Staib C, Sutter G: Modified vaccinia virus Ankara as
antigen delivery system: how can we best use its potential?
Curr Opin Biotechnol 2004, 15(6):506-512.
12. Kastenmuller W, Drexler I, Ludwig H, Erfle V, Peschel C, Bernhard
H, Sutter G: Infection of human dendritic cells with recom-
binant vaccinia virus MVA reveals general persistence of
viral early transcription but distinct maturation-dependent
cytopathogenicity.  Virology 2006, 350(2):276-288.
13. Henderson DA: The looming threat of bioterrorism.  Science
1999, 283(5406):1279-1282.
14. Parrino J, McCurdy LH, Larkin BD, Gordon IJ, Rucker SE, Enama ME,
Koup RA, Roederer M, Bailer RT, Moodie Z, Gu L, Yan L, Graham BS:
Safety, immunogenicity and efficacy of modified vaccinia
Ankara (MVA) against Dryvax challenge in vaccinia-naive
and vaccinia-immune individuals.  Vaccine 2007,
25(8):1513-1525.
15. Carroll MW, Overwijk WW, Chamberlain RS, Rosenberg SA, Moss
B, Restifo NP: Highly attenuated modified vaccinia virus
Ankara (MVA) as an effective recombinant vector: a murine
tumor model.  Vaccine 1997, 15(4):387-394.
16. Carroll MW, Moss B: Poxviruses as expression vectors.  Curr
Opin Biotechnol 1997, 8(5):573-577.
17. Guermonprez P, Valladeau J, Zitvogel L, Thery C, Amigorena S: Anti-
gen presentation and T cell stimulation by dendritic cells.
Annu Rev Immunol 2002, 20:621-667.
18. Drillien R, Spehner D, Hanau D: Modified vaccinia virus Ankara
induces moderate activation of human dendritic cells.  J Gen
Virol 2004, 85(Pt 8):2167-2175.
19. Liu L, Xu Z, Fuhlbrigge RC, Pena-Cruz V, Lieberman J, Kupper TS:
Vaccinia virus induces strong immunoregulatory cytokine
production in healthy human epidermal keratinocytes: a
novel strategy for immune evasion.  Journal of virology 2005,
79(12):7363-7370.
20. Engelmayer J, Larsson M, Subklewe M, Chahroudi A, Cox WI, Stein-
man RM, Bhardwaj N: Vaccinia virus inhibits the maturation of
human dendritic cells: a novel mechanism of immune eva-
sion.  J Immunol 1999, 163(12):6762-6768.
21. Humrich JY, Thumann P, Greiner S, Humrich JH, Averbeck M,
Schwank C, Kampgen E, Schuler G, Jenne L: Vaccinia virus impairs
directional migration and chemokine receptor switch of
human dendritic cells.  Eur J Immunol 2007, 37(4):954-965.
22. Walzer T, Galibert L, De Smedt T: Poxvirus semaphorin A39R
inhibits phagocytosis by dendritic cells and neutrophils.  Eur J
Immunol 2005, 35(2):391-398.
23. Blanchard TJ, Alcami A, Andrea P, Smith GL: Modified vaccinia
virus Ankara undergoes limited replication in human cells
and lacks several immunomodulatory proteins: implications
for use as a human vaccine.  J Gen Virol 1998, 79(Pt 5):1159-1167.
24. Chahroudi A, Garber DA, Reeves P, Liu L, Kalman D, Feinberg MB:
Differences and similarities in viral life cycle progression and
host cell physiology after infection of human dendritic cells
with modified vaccinia virus Ankara and vaccinia virus.  Jour-
nal of virology 2006, 80(17):8469-8481.
25. Jung S, Unutmaz D, Wong P, Sano G, De los Santos K, Sparwasser T,
Wu S, Vuthoori S, Ko K, Zavala F, Pamer EG, Littman DR, Lang RA:
In vivo depletion of CD11c(+) dendritic cells abrogates prim-
ing of CD8(+) T cells by exogenous cell-associated antigens.
Immunity 2002, 17(2):211-220.
26. Tian T, Woodworth J, Skold M, Behar SM: In vivo depletion of
CD11c+ cells delays the CD4+ T cell response to Mycobacte-
rium tuberculosis and exacerbates the outcome of infection.
J Immunol 2005, 175(5):3268-3272.
27. Belyakov IM, Wyatt LS, Ahlers JD, Earl P, Pendleton CD, Kelsall BL,
Strober W, Moss B, Berzofsky JA: Induction of a mucosal cyto-
Additional file 1
IFN-α was not detected in the supernatant of VV-infected DCs. (A) 
Immature BMDCs or purified CD11c+ splenic DCs were either mock 
treated or infected with rVV-EGFP (a kind gift of Dr. Lawrence Corey, 
University of Washington, Seattle, WA) at a MOI of 10. Supernatant 
samples were collected at 10 and 24 h post infection, and IFN-α levels 
were measured by ELISA. These data are representative of three independ-
ent experiments. (B) VV-infected BMDCs produced a soluble factor(s) 
that abrogated the detection of IFN-α in the supernatant. Immature 
BMDCs were infected with rMVA-GFP or rVV-EGFP at a MOI of 10. 
Supernatant samples were collected at 24 h post infection. Various 
amounts of rmIFN-α were added into supernatant samples and ELISA 
was subsequently performed to detect IFN-α.
Click here for file
[http://www.biomedcentral.com/content/supplementary/1471-
2172-9-15-S1.pdf]Publish with BioMed Central    and   every 
scientist can read your work free of charge
"BioMed Central will be the most significant development for 
disseminating the results of biomedical research in our lifetime."
Sir Paul Nurse, Cancer Research UK
Your research papers will be:
available free of charge to the entire biomedical community
peer reviewed and published  immediately upon acceptance
cited in PubMed and archived on PubMed Central 
yours — you keep the copyright
Submit your manuscript here:
http://www.biomedcentral.com/info/publishing_adv.asp
BioMedcentral
BMC Immunology 2008, 9:15 http://www.biomedcentral.com/1471-2172/9/15
Page 14 of 14
(page number not for citation purposes)
toxic T-lymphocyte response by intrarectal immunization
with a replication-deficient recombinant vaccinia virus
expressing human immunodeficiency virus 89.6 envelope
protein.  Journal of virology 1998, 72(10):8264-8272.
28. Chahroudi A, Chavan R, Kozyr N, Waller EK, Silvestri G, Feinberg
MB:  Vaccinia virus tropism for primary hematolymphoid
cells is determined by restricted expression of a unique virus
receptor.  Journal of virology 2005, 79(16):10397-10407.
29. Amanna IJ, Slifka MK, Crotty S: Immunity and immunological
memory following smallpox vaccination.  Immunol Rev 2006,
211:320-337.
30. Crotty S, Felgner P, Davies H, Glidewell J, Villarreal L, Ahmed R: Cut-
ting edge: long-term B cell memory in humans after small-
pox vaccination.  J Immunol 2003, 171(10):4969-4973.
31. Precopio ML, Betts MR, Parrino J, Price DA, Gostick E, Ambrozak
DR, Asher TE, Douek DC, Harari A, Pantaleo G, Bailer R, Graham BS,
Roederer M, Koup RA: Immunization with vaccinia virus
induces polyfunctional and phenotypically distinctive CD8+
T cell responses.  J Exp Med 2007, 204(6):1405-1416.
32. Behboudi S, Moore A, Gilbert SC, Nicoll CL, Hill AV: Dendritic cells
infected by recombinant modified vaccinia virus Ankara
retain immunogenicity in vivo despite in vitro dysfunction.
Vaccine 2004, 22(31-32):4326-4331.
33. Behboudi S, Moore A, Hill AV: Splenic dendritic cell subsets
prime and boost CD8 T cells and are involved in the genera-
tion of effector CD8 T cells.  Cell Immunol 2004, 228(1):15-19.
34. Bender A, Albert M, Reddy A, Feldman M, Sauter B, Kaplan G, Hell-
man W, Bhardwaj N: The distinctive features of influenza virus
infection of dendritic cells.  Immunobiology 1998, 198(5):552-567.
35. Ho LJ, Wang JJ, Shaio MF, Kao CL, Chang DM, Han SW, Lai JH: Infec-
tion of human dendritic cells by dengue virus causes cell mat-
uration and cytokine production.  J Immunol 2001,
166(3):1499-1506.
36. Geijtenbeek TB, Kwon DS, Torensma R, van Vliet SJ, van Duijnhoven
GC, Middel J, Cornelissen IL, Nottet HS, KewalRamani VN, Littman
DR, Figdor CG, van Kooyk Y: DC-SIGN, a dendritic cell-specific
HIV-1-binding protein that enhances trans-infection of T
cells.  Cell 2000, 100(5):587-597.
37. Moutaftsi M, Mehl AM, Borysiewicz LK, Tabi Z: Human cytomega-
lovirus inhibits maturation and impairs function of mono-
cyte-derived dendritic cells.  Blood 2002, 99(8):2913-2921.
38. Servet-Delprat C, Vidalain PO, Azocar O, Le Deist F, Fischer A, Rab-
ourdin-Combe C: Consequences of Fas-mediated human den-
dritic cell apoptosis induced by measles virus.  Journal of virology
2000, 74(9):4387-4393.
39. Servet-Delprat C, Vidalain PO, Bausinger H, Manie S, Le Deist F, Azo-
car O, Hanau D, Fischer A, Rabourdin-Combe C: Measles virus
induces abnormal differentiation of CD40 ligand-activated
human dendritic cells.  J Immunol 2000, 164(4):1753-1760.
40. Oie KL, Pickup DJ: Cowpox virus and other members of the
orthopoxvirus genus interfere with the regulation of NF-
kappaB activation.  Virology 2001, 288(1):175-187.
41. Yoshimura S, Bondeson J, Foxwell BM, Brennan FM, Feldmann M:
Effective antigen presentation by dendritic cells is NF-kap-
paB dependent: coordinate regulation of MHC, co-stimula-
tory molecules and cytokines.  Int Immunol 2001, 13(5):675-683.
42. Seet BT, Johnston JB, Brunetti CR, Barrett JW, Everett H, Cameron
C, Sypula J, Nazarian SH, Lucas A, McFadden G: Poxviruses and
immune evasion.  Annual Review of Immunology 2003, 21:377-423.
43. Colamonici OR, Domanski P, Sweitzer SM, Larner A, Buller RM: Vac-
cinia virus B18R gene encodes a type I interferon-binding
protein that blocks interferon alpha transmembrane signal-
ing.  J Biol Chem 1995, 270(27):15974-15978.
44. Symons JA, Alcami A, Smith GL: Vaccinia virus encodes a soluble
type I interferon receptor of novel structure and broad spe-
cies specificity.  Cell 1995, 81(4):551-560.
45. Antoine G, Scheiflinger F, Dorner F, Falkner FG: The complete
genomic sequence of the modified vaccinia Ankara strain:
comparison with other orthopoxviruses.  Virology 1998,
244(2):365-396.
46. Lande R, Giacomini E, Grassi T, Remoli ME, Iona E, Miettinen M,
Julkunen I, Coccia EM: IFN-alpha beta released by Mycobacte-
rium tuberculosis-infected human dendritic cells induces the
expression of CXCL10: selective recruitment of NK and acti-
vated T cells.  Journal of Immunology 2003, 170(3):1174-1182.
47. Montoya M, Schiavoni G, Mattei F, Gresser I, Belardelli F, Borrow P,
Tough DF: Type I interferons produced by dendritic cells pro-
mote their phenotypic and functional activation.  Blood 2002,
99(9):3263-3271.
48. Dobbelstein M, Shenk T: Protection against apoptosis by the
vaccinia virus SPI-2 (B13R) gene product.  Journal of virology
1996, 70(9):6479-6485.
49. Norbury CC, Malide D, Gibbs JS, Bennink JR, Yewdell JW: Visualiz-
ing priming of virus-specific CD8+ T cells by infected den-
dritic cells in vivo.  Nat Immunol 2002, 3(3):265-271.
50. Norbury CC, Basta S, Donohue KB, Tscharke DC, Princiotta MF,
Berglund P, Gibbs J, Bennink JR, Yewdell JW: CD8+ T cell cross-
priming via transfer of proteasome substrates.  Science 2004,
304(5675):1318-1321.
51. Kennedy R, Poland GA: T-Cell epitope discovery for variola and
vaccinia viruses.  Rev Med Virol 2007, 17(2):93-113.
52. Chavan R, Marfatia KA, An IC, Garber DA, Feinberg MB: Expression
of CCL20 and granulocyte-macrophage colony-stimulating
factor, but not Flt3-L, from modified vaccinia virus ankara
enhances antiviral cellular and humoral immune responses.
Journal of virology 2006, 80(15):7676-7687.
53. Carroll MW, Moss B: Host range and cytopathogenicity of the
highly attenuated MVA strain of vaccinia virus: propagation
and generation of recombinant viruses in a nonhuman mam-
malian cell line.  Virology 1997, 238(2):198-211.
54. Pulendran B, Lingappa J, Kennedy MK, Smith J, Teepe M, Rudensky A,
Maliszewski CR, Maraskovsky E: Developmental pathways of
dendritic cells in vivo: distinct function, phenotype, and local-
ization of dendritic cell subsets in FLT3 ligand-treated mice.
J Immunol 1997, 159(5):2222-2231.
55. Pulendran B, Smith JL, Caspary G, Brasel K, Pettit D, Maraskovsky E,
Maliszewski CR: Distinct dendritic cell subsets differentially
regulate the class of immune response in vivo.  Proceedings of
the National Academy of Sciences of the United States of America 1999,
96(3):1036-1041.
56. Liu L, Usherwood EJ, Blackman MA, Woodland DL: T-cell vaccina-
tion alters the course of murine herpesvirus 68 infection and
the establishment of viral latency in mice.  Journal of virology
1999, 73(12):9849-9857.
57. Sailaja G, Husain S, Nayak BP, Jabbar AM: Long-term maintenance
of gp120-specific immune responses by genetic vaccination
with the HIV-1 envelope genes linked to the gene encoding
Flt-3 ligand.  J Immunol 2003, 170(5):2496-2507.
58. Liu L, Chahroudi A, Silvestri G, Wernett ME, Kaiser WJ, Safrit JT,
Komoriya A, Altman JD, Packard BZ, Feinberg MB: Visualization
and quantification of T cell-mediated cytotoxicity using cell-
permeable fluorogenic caspase substrates.  Nat Med 2002,
8(2):185-189.